XERS - Xeris Biopharma: Assessing The Growth And Valuation Disparity
Summary
- Xeris Biopharma expects to report record net product revenue for 2022 thanks to strong growth across their portfolio of approved products.
- Xeris believes they are still on track to hit its goal of cash flow breakeven by the end of 2023.
- XERS is trading around $1.25 per share and has a market cap of roughly $158M. I believe there is a major disconnect between the stock's valuation and growth prospects.
- I am defending XERS as a “Top Idea” in my Compounding Healthcare Marketplace Service.
- I update investors on my strategy and plans for 2023.
For further details see:
Xeris Biopharma: Assessing The Growth And Valuation Disparity